May #123 : Prescription For Change - by Lucile Scott

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 
One Tough Pirate



Seeing the Future

Mentors-May 2006

Medicine Men




Custom Care

Early Birds

Simply Irresistible

The Topic of Cancer

Sow Your Oats

Trainer’s Bench-May 2006

Hustle and Flow

Animal Attraction

Purrrfect Health

Women on Top

PEP Rally

POZ Personals Catch of the Month-May 2006

First Aid for Your Medicaid

Shall We Dance?




A Will & Grace-full Exit?

Ratings for a Serial Virus

Squeaky Clean?

Prescription For Change

Bono’s Red Alert

One Hot ASO

Banned Aid

It’s Not You; It’s Me

Near Dead Again




Editor's Letter-May 2006

Mailbox-May 2006



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

May 2006


Prescription For Change

by Lucile Scott

Bashing generic promises

Pharmaceutical companies Roche and Gilead fielded a whopping dose of health activists’ wrath in January for breaking promises to offer affordable AIDS meds. “In the past four years, pressure on companies to do their part in providing drug access has increased,” says Kate Evans of the nongovernmental organization (NGO) Médecins Sans Frontières. “But we repeatedly see no follow-up.” Advocates contend that companies dangle access policies for PR cred, then don’t implement them.

In April 2003, Gilead said it would file to distribute the HIV med tenofovir in needy countries. But by January 2006, the company had registered in only six of the 97 countries named. Gilead says it will hit the others this year. In January, Roche announced plans to give developing countries technical tips on producing saquinavir. But the Berne Declaration, a Swiss NGO, declared the tips irrelevant, since many nations lack the basic capacity to produce drugs and added that Roche hadn’t even relinquished the patent. Roche countered that it doesn’t enforce the patent in the countries and that many can crank out the drugs. Regardless, accountability is one pill they may have to swallow.


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.